Publication | Closed Access

Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial

Hematological MalignancyThrombosisAcute Lymphoblastic LeukaemiaVenous ThrombosisApixaban VersusPediatric HematologyHematologyPediatricsPharmacotherapyMedicineAnticoagulantPhase 3